Navigation Links
New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
Date:11/9/2010

oney/Waters Group212.886.2228, sfox@cooneywaters.comAbout Rheumatoid ArthritisRA affects more than 1.3 million Americans, and it is estimated that 5 million people suffer from RA globally.  Prevalence is not split evenly between genders, since women are three times more likely to be affected than men.  Although RA can affect people of all ages, the onset of the disease usually occurs between 35-55 years of age.

About REALISTIC StudyREALISTIC (RA Evaluation in Subjects Receiving TNF Inhibitor Certolizumab Pegol) is a multicenter phase IIIb trial in patients with active rheumatoid arthritis who have shown inadequate response to disease-modifying antirheumatic drugs, including patients with/without prior TNF-inhibitor exposure, with/without concomitant methotrexate or other disease-modifying anti-rheumatic drugs (DMARDs); and varying lengths of disease duration. The study demonstrated that – in a diverse group of RA patients reflecting those seen in daily clinical practice (including those with prior TNF- inhibitor use) – addition of CZP to current therapy was associated with a rapid clinical response consistent in all strata, improved function and reduced disease activity.

About Cimzia®Certolizumab pegol is the only PEGylated anti-TNF (Tumor Necrosis Factor).  It has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNF-alpha.  Over the past decade, TNF-alpha has emerged as a major target of basic research and clinical investigation.  This cytokine plays a key role in mediating pathological inflammation, and excess TNF-alpha production has been directly implicated in a wide variety of diseases.  The U.S. Food and Drug Administration (FDA) has approved certolizumab pegol for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult pati
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
2. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
3. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
4. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
5. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
6. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
7. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
8. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
9. Marken Rapidly Responds to Global Supply Chain Security Measures
10. Biosimilar Erosion of Branded ESA Market Share Will be More Rapid in the U.S. Than in Europe
11. Results of Boehringer Ingelheim Oral Hepatitis C Protease Inhibitor and Polymerase Inhibitor Combination Phase Ib Trial Shows Rapid Viral Response Without Use of Pegylated Interferon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 2014 Research and Markets has announced ... report to their offering. Animal vaccines ... Animal vaccines are generally prepared from weakened or dead microbes ... state. Some of the animal vaccines are also formulated using ... or toxic components. These components act as ...
(Date:9/16/2014)... 16, 2014  Denovo Biopharma, LLC, today announced ... drug, from Eli Lilly and Company (NYSE:  LLY). ... commercialize enzastaurin globally, including transfer of all intellectual ... Lilly developed enzastaurin in a variety ... 3 clinical trials for diffuse large B-cell lymphoma ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
Breaking Medicine Technology:Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4
... 2011  GP Strategies Corporation (NYSE: GPX ), ... GP Strategies Corporation with and into its ... company structure. General Physics, which is the sole operating ... corporation and will be renamed GP Strategies Corporation when ...
... BOWIE, Md., Dec. 15, 2011  MedAssurant, Inc., ... today announced that Healthcare Partners, IPA (HCPIPA), ... associations (IPA) in the Northeast, has selected ... (CARA™)  solutions to proactively identify gaps in ...
Cached Medicine Technology:GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 2GP Strategies Shareholders Approve Elimination of Holding Company Structure and Renaming of General Physics Corporation 3Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 2Healthcare Partners, IPA, Implements MedAssurant's Innovative, Data-Driven Solutions 3
(Date:9/16/2014)... 16th, 2014; San Francisco) In a healthcare ... weighed against potential benefit, a Yale study has ... less-aggressive radiation procedures on elderly women with early-stage ... presented at the 56th annual conference of the ... (Abstract 131: Evaluating National Practice in Radiotherapy for ...
(Date:9/16/2014)... 2014 Recently, iFitDress.com, one of the most ... one shoulder evening gown collection. According to the ... at discounted rates (up to 69% off) at present. Additionally, ... , “I am a frequent caller of your site. ... my dress, I feel quite happy. All items are of ...
(Date:9/16/2014)... 16, 2014 The second federal bellwether ... & Johnson subsidiary Ethicon concluded with the jury in ... and awarding her $3.27 million in damages, according to ... report, “jurors found Ethicon liable for selling faulty devices ... users were at risk from side effects that include ...
(Date:9/16/2014)... forensic techniques are shedding light on a 500-year-old mystery: ... the last English monarch to die in battle? ... whole-body CT scans and micro-CT imaging of injured bones, ... suffered at the Battle of Bosworth Field, where he ... revealed that two skull injuries could have killed the ...
(Date:9/16/2014)... Paradigm Physical Therapy is proud to ... treatment for their patients. Dry needling is a procedure ... of musculoskeletal problems. , In this invasive procedure, a ... skin and muscle to create a trigger point. Using ... helps to deactivate and release the trigger point within ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2Health News:Ethicon to Appeal Bellwether Trial Verdict of $3.27 Million, Rottenstein Law Group LLP Notes 2Health News:Modern Forensics Provides Clues to Death of Richard III 2Health News:Paradigm Physical Therapy Introduces Dry Needling 2
... cells (CTCs) may be a promising alternative, noninvasive source ... presented at the Fourth AACR International Conference on Molecular ... idea is that CTCs can provide real-time information about ... biopsy," said Siminder Kaur Atwal, Ph.D., senior research associate ...
... study carried out by Spanish researchers has shown that the ... for good or for bad, the way in which work-related ... manifests itself. Noise-related hearing loss is the most common occupational ... presence of metalworking fluids exhibit a delay in hearing alteration ...
... TUESDAY, Sept. 28 (HealthDay News) -- American middle-school students who ... mentally better off than those who don,t, a new study ... explore the potential health impact that team sports activity might ... ages of 12 and 14. "Other studies have looked ...
... By Steven Reinberg HealthDay Reporter , ... comparison of drug-coated stents -- the metal mesh tubes ... model using the drug sirolimus came out on top, ... coated with zotarolimus, fell short, the study found. ...
... discernible influence on how African American patients with asthma ... study. Researchers found that improved lung function in ... series of baseline breathing function measures, not genetic ancestry. ... of Allergy & Clinical Immunology , http://www.aaaai.org/media/jaci/ ...
... By Serena Gordon HealthDay Reporter , MONDAY, ... Pediatrics doesn,t want children exposed to tobacco ads at ... marketing and advertisements for erectile dysfunction drugs and other ... of the recommendations in its new policy statement, "Children, ...
Cached Medicine News:Health News:Circulating tumor cells can provide 'real-time' information on patient's current disease state 2Health News:Noise and chemicals: Workers are losing their hearing 2Health News:Team Sports Pep Up Middle-School Kids 2Health News:Team Sports Pep Up Middle-School Kids 3Health News:In Test of Stents, Old Standby Wins Out 2Health News:No link between genetic ancestry, asthma response in African-Americans 2Health News:Pediatricians Want to Restrict Ads for Tobacco, Booze, Viagra 2Health News:Pediatricians Want to Restrict Ads for Tobacco, Booze, Viagra 3
The GII titanium anchor with nitinol arcs is used for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor used by...
... greater definition than a standard Galilean ... The Hi-Res five element system provides ... lightweight system., ,Order frame separately., ,Keeler ... in a soft carrying case and ...
The Nevyas Drape Support is the simple and inexpensive way to establish a zone of comfort for your patients during ophthalmic surgery which requires draping over the nose and mouth. Packaged in sets ...
... Wristrest has become an important standard in busy ... encircles the patient's head and supports arms and ... easy draping especially when fluids are collected. The ... way for easy patient transfer on and off ...
Medicine Products: